Kamalesh K. Sankhala

Author

Also Known As

K. K. Sankhala, K. Kumar Sankhala, K. Sankhala, K.K. Sankhala, Kamalesh K Sankhala, Kamalesh K. Sankhala, Kamalesh Kumar Sankhala, Kamalesh Sankhala, Kamlesh Kumar Sankhala, Kamlesh Sankhala

142

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Sarcoma Oncology Center The University of Texas Health Science Center at San Antonio The University of Texas MD Anderson Cancer Center Icahn School of Medicine at Mount Sinai Moffitt Cancer Center

About

Kamalesh K. Sankhala is an author at Sarcoma Oncology Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1K
2	Immunology	7	7	157
3	Health Sciences	5	5	182
4	Biochemistry	1	1	81
5	Cell Biology	1	1	18

Kamalesh K. Sankhala

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Journal of Clinical Oncology	2011	246
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors Razelle Kurzrock, N. Gabrail, Chandtip Chandhasin, Molecular Cancer Therapeutics Neuro-oncologyOncologyBrain MetastasesMedicineNovel Conjugate	2011	168
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Emanuela Palmerini, Neal Shiv Chawla, Stefano Ferrari, European Journal of Cancer Surgical OncologyTumoral PathologyMalignant DiseaseMedicineAdvanced/unresectable Giant-cell Tumour	2017	164
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer Monica Mita, Anil A. Joy, Alain C. Mita, Clinical Breast Cancer Advanced Breast CancerBreast OncologyOncologyPhase Ii TrialMedicine	2013	151
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma Sant P. Chawla, Zsuzsanna Pápai, Guzel Mukhametshina, JAMA Oncology	2015	105
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors Alain C. Mita, Chris H. Takimoto, Monica Mita, Clinical Cancer Research	2010	101
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin Anthony W. Tolcher, Christopher J. Sweeney, K. Papadopoulos, Clinical Cancer Research	2011	85
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin Kamalesh K. Sankhala, Akira Mita, R. Adinin, Journal of Clinical Oncology Lipid PreparationTumor BiologyPharmaceutical ScienceOncologyBiochemistry	2009	81
Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas Sant P. Chawla, A. W. Tolcher, Arthur P. Staddon, Journal of Clinical Oncology PathologyPharmacotherapyTumor BiologyOncologyMetronomic Therapy	2006	73
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Antje Wick, Oliver Bähr, Martin Schüler, Clinical Cancer Research	2021	64

Page 1